Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - cytarabine, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; nitrogen - switzerland: ? induction and maintenance of remission in combination with other cytotoxic agents in adults and children with acute myeloid leukaemia. ? treatment of acute lymphoblastic leukaemia, lymphoid blast crisis of chronic myeloid leukaemia, and erythroleukaemia. cytosar solution may be used alone or in combination with other cytotoxic agents. ? in children with non-hodgkin's lymphoma in combination with other cytotoxic agents. ? high-dose treatment for acute leukaemia. ? intrathecal prophylaxis and treatment of meningeal leukaemia, alone or in combination with hydrocortisone sodium succinate and methotrexate.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - cytarabine, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; nitrogen - switzerland: ? induction and maintenance of remission in combination with other cytotoxic agents in adults and children with acute myeloid leukaemia. ? treatment of acute lymphoblastic leukaemia, lymphoid blast crisis of chronic myeloid leukaemia, and erythroleukaemia. cytosar solution may be used alone or in combination with other cytotoxic agents. ? in children with non-hodgkin's lymphoma in combination with other cytotoxic agents. ? high-dose treatment for acute leukaemia. ? intrathecal prophylaxis and treatment of meningeal leukaemia, alone or in combination with hydrocortisone sodium succinate and methotrexate.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; nitrogen - canada: cytosar (cytarabine) is indicated primarily for induction and maintenance of remission in acute leukemia in both adults and children. it has been found useful in the treatment of acute myelocytic leukemia, chronic myelocytic leukemia (blast phase), acute lymphocytic leukemia and erythroleukemia. cytosar may be used alone or in combination with other antineoplastic agents; the best results are obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that included cytosar. cytosar has been used intrathecally in newly diagnosed children with acute lymphocytic leukemia as well as in the treatment of meningeal leukemia. cytosar, in high dose 2-3 g/m2 as an i.v. infusion over 1-3 hours given every 12 hours for 2-6 days with or without additional cancer chemotherapeutic agents, has been shown to be effective in the treatment of poor-risk leukemia, refractory leukemia, and relapsed acute leukemia.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; nitrogen - canada: cytosar (cytarabine) is indicated primarily for induction and maintenance of remission in acute leukemia in both adults and children. it has been found useful in the treatment of acute myelocytic leukemia, chronic myelocytic leukemia (blast phase), acute lymphocytic leukemia and erythroleukemia. cytosar may be used alone or in combination with other antineoplastic agents; the best results are obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that included cytosar. cytosar has been used intrathecally in newly diagnosed children with acute lymphocytic leukemia as well as in the treatment of meningeal leukemia. cytosar, in high dose 2-3 g/m2 as an i.v. infusion over 1-3 hours given every 12 hours for 2-6 days with or without additional cancer chemotherapeutic agents, has been shown to be effective in the treatment of poor-risk leukemia, refractory leukemia, and relapsed acute leukemia.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; nitrogen - switzerland: - induction and maintenance of remission in combination with other cytotoxic agents in adults and children with acute myeloid leukaemia. - treatment of acute lymphoblastic leukaemia, lymphoid blast crisis of chronic myeloid leukaemia, and erythroleukaemia. cytosar solution may be used alone or in combination with other cytotoxic agents. - in children with non-hodgkin's lymphoma in combination with other cytotoxic agents. - high-dose treatment for acute leukaemia. - intrathecal prophylaxis and treatment of meningeal leukaemia, alone or in combination with hydrocortisone sodium succinate and methotrexate.

Kanada - Ingliż - Health Canada

pfizer canada ulc - cytarabine - solution - 100mg - cytarabine 100mg - antineoplastic agents

Kanada - Ingliż - Health Canada

sandoz canada incorporated - cytarabine - solution - 100mg - cytarabine 100mg - antineoplastic agents

Kanada - Ingliż - Health Canada

mylan pharmaceuticals ulc - cytarabine - solution - 100mg - cytarabine 100mg - antineoplastic agents

Kanada - Ingliż - Health Canada

agila jamp canada inc - cytarabine - solution - 100mg - cytarabine 100mg - antineoplastic agents

Kanada - Ingliż - Health Canada

pharmascience inc - cytarabine - solution - 20mg - cytarabine 20mg - antineoplastic agents